News
PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback